Korean biotech firm Alteogen said April 26 has signed a letter of intent to license its long-acting drug for growth hormone deficiency with Brazil’s Cristalia for its development and sale in Latin Ame
THE INVESTOR] Alteogen is accelerating the development of a biosimilar version of the world’s top breast cancer drug Herceptin to join two other Korean firms in challenging big pharma Roche.
Alteogen, a Korean developer of biosimilars, said Wednesday it would transfer the technology of its ALT-L2, a biosimilar product of breast and gastric cancer treatment Herceptin, to China’s Qilu Pharm
Date Alteogen patents (updated weekly) - BOOKMARK this page
 1  2  3  4